Acidophil, LLC is an intellectual property development company whose goal is to translate innovative life science technologies into products and businesses. Acidophil’s founders are Nobel Laureate Sydney Brenner, MD, Ph.D., and Philip Goelet, PhD. Acidophil’s team identifies unmet needs, develops or in-licenses enabling intellectual property, and assembles teams consisting of external and internal experts in order to establish proof-of-principle data, and develop commercial programs.

Anthem Capital Management LLC Anthem’s team has accumulated more than 75 years of venture capital experience. We were early venture investors in such companies as Apple Computer, Samna (Lotus’s word processor), Sequoia Software, HealthSouth, Phycor and Corporate Childcare Services. Today, we bring this experience to bear on opportunities that match the following investment profile. Anthem invests exclusively in the Mid-Atlantic states and serves this area from offices located in three of the region’s key markets: the Baltimore–Washington corridor, the Greater Philadelphia market, and the Greater Pittsburgh market. Anthem seeks opportunities in IT and healthcare/life sciences industries. IT investments are most frequently made in enterprise software or network management software companies. Medical investments tend to fall into three categories: medical devices, biotechnology or healthcare. Anthem invests in early to expansion stage opportunities. Typically, our initial investment is made in the Series A or Series B institutional venture capital round. We have led or co-led 80% of the investments we have made, but also will participate in syndicates where appropriate.

Domain Associates is a venture capital firm with an exclusive focus on life science companies. With $2.5 billion under management, Domain is headquartered in Princeton, NJ, and San Diego, CA. Domain’s three major investment segments are pharmaceuticals, specialty pharmaceuticals, and medical devices. Additional areas of interest include biomaterials, bioinstrumentation, and diagnostics. Among them, the partners of Domain have nearly 200 person-years of experience among them in the healthcare/venture capital industries, and have been involved in the formation and growth of more than 220 life-sciences companies. The highly focused network, experience, and reputation of this team have made it one of the top private-equity groups participating in the healthcare field.

Maryland Health Care Product Development Corp is a supporting organization of the Tech Council of Maryland (TCM). Its goal is to stimulate growth of the biomedical industry in the state through early stage investment in promising Maryland biomedical and medical technology companies. The Corporation will support TCM’s work in Maryland and the region by assisting emerging companies with management advice, market research, technical assessments, and early stage financing.

MedImmune Ventures, a wholly-owned venture capital fund within the AstraZeneca Group, invests in private companies which develop small and large molecules, vaccines, pharmaceutical technologies and platforms. We also seek investments in medical device, diagnostic, imaging and healthcare IT companies which pertain to the discovery, development and commercialization of pharmaceutical products. MedImmune Ventures invests in companies with early to late stage products and technologies, in early (e.g. seed) to late (e.g. mezzanine) rounds of financing. With $400M under management in an evergreen fund, MedImmune Ventures has invested in over 30 companies since 2002.

NewSpring Capital, headquartered in Radnor, PA, with offices in Short Hills, NJ, and Washington, D.C., is a leading provider of private equity capital focused in the Mid-Atlantic region. Through its family of funds, NewSpring Capital has more than $500 million across three distinct investment strategies. NewSpring’s Healthcare Fund provides equity capital to healthcare companies within the specialty pharmaceuticals, healthcare services, and medical device sectors. The firm’s highly cohesive investment team has a strong track record of investing in both private and public transactions, collectively representing more than 100 years of experience, and investing more than $1 billion.

Quaker BioVentures is a venture capital firm investing in life science companies. The firm leads investments across the spectrum of the life science industry, including biopharmaceuticals, medical devices, human diagnostics, specialty pharmaceuticals, and healthcare services. Quaker BioVentures invests in companies at all stages of development. The firm was formed in 2003, and is currently investing from Quaker BioVentures II, a $420M fund formed in 2007. Quaker BioVentures manages over $700M in committed capital.

Red Abbey Venture Partners is a life sciences investment partnership founded in 2004. The firm’s mission is to generate superior, risk-adjusted returns by investing across the life sciences spectrum in young companies that are developing the next generation of drugs and devices, as well as the tools that support these efforts. The partnership has a select group of family offices and individual investors who have committed $50 million to the fund.